BLCO earnings analysis
What we found in BLCO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bausch + Lomb's Q1 2026 results reflected a considerable revenue increase to $1.244 billion, surpassing estimates by approximately 3%. This marks a 9% growth compared to the same quarter last year, although the company reported a significant net loss of $71 million with an EPS of -0.06.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Q1 2026 revenue reached $1.244 billion, up 9% from $1.139 billion in Q1 2025.
- Improved Gross Margin
- Gross margin increased to 59.5% in Q1 2026, from 57.6% in Q1 2025.
- Pharmaceutical Segment Growth
- Pharmaceutical sales increased by 30% year-over-year, significantly contributing to revenue.
- No Change in Risk Factors
- There were no new risk factors disclosed since the last filing.
- Increased Cash Position
- Cash and cash equivalents totaled $200 million, up from $150 million in Q1 2025.
- Raised Full-Year Guidance
- Management anticipates increased full-year revenue and adjusted EBITDA based on strong Q1 performance.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Net Loss Persisted
- Reported a net loss of $71 million in Q1 2026, compared to a $69 million loss in Q1 2025.
- Negative EPS
- Diluted EPS was -0.06, worse than the expected EPS of 0.06.
- Geopolitical Risks
- Continued impact from geopolitical tensions, particularly with revenues from impacted regions accounting for less than 2% of total revenues.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.06
- Gross margin
- 59.5%
What they said about what is next.
Full-year 2026 revenue and EBITDA guidance raised due to strong performance in Q1.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 18, 2026
- Bausch + Lomb reported full-year revenue strength with 2025 sales of approximately $5.11B versus $4.80B in 2024 (+~6.5% YoY) and a Q4 2025 revenue beat at $1,405,000,000. Profitability and cash-flow remain uneven: GAAP…
- 10-Q · July 30, 2025
- Bausch + Lomb reported Q2 revenue of $1,278,000,000 and GAAP EPS of $0.07 (in line with consensus). The balance sheet shows cash and cash equivalents down to $266 million and long-term debt increased to $4,931 million…
- 10-Q · April 30, 2025
- Bausch + Lomb reported Q1 2025 results with revenue of $1.14 billion, a 3.6% decrease from $1.18 billion in Q4 2024, and a notable increase from $1.1 billion in Q1 2024. The company posted a net loss of $212 million,…
- 10-K · February 21, 2024
- Bausch + Lomb positions itself as a full‑spectrum global eye‑health company with ~400 products, a presence in approximately 100 countries and ~13,300 employees. The 10‑K highlights the recently consummated XIIDRA…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BLCO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever